Who is asking about medicinal cannabis in palliative care?
cancer
carer
medicinal cannabis
palliative care
patient
Journal
Internal medicine journal
ISSN: 1445-5994
Titre abrégé: Intern Med J
Pays: Australia
ID NLM: 101092952
Informations de publication
Date de publication:
02 2020
02 2020
Historique:
received:
23
05
2019
revised:
08
07
2019
accepted:
12
07
2019
entrez:
11
2
2020
pubmed:
11
2
2020
medline:
27
1
2021
Statut:
ppublish
Résumé
Following legislative changes in the availability and prescribing of medicinal cannabis in Australia, we sought to understand prospectively the nature of information seeking and requests for medicinal cannabis in consultations between palliative care clinicians and patients with cancer. The 104 discussions were overwhelmingly initiated by patients and carers (93%) and were for a variety of symptoms, reflecting high levels of patient interest in the use of medicinal cannabis in cancer.
Substances chimiques
Medical Marijuana
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
243-246Subventions
Organisme : Western and Central Melbourne Integrated Cancer Service (WCMICS)
Pays : International
Informations de copyright
© 2020 Royal Australasian College of Physicians.
Références
Pergam SA, Woodfield MC, Lee CM, Cheng GS, Baker KK, Marquis SR et al. Cannabis use among patients at a comprehensive cancer center in a state with legalized medicinal and recreational use. Cancer 2017; 123: 4488-97.
Machado Rocha FC, Stefano S, De Cassia Haiek R, Rosa Oliveira L, Da Silveira D. Therapeutic use of Cannabis sativa on chemotherapy-induced nausea and vomiting among cancer patients: systematic review and meta-analysis. Eur J Cancer Care 2008; 17: 431-43.
Lutge E, Gray A, Siegfried N. The medical use of cannabis for reducing morbidity and mortality in patients with HIV/AIDS. Cochrane Database Syst Rev 2013; 1-35.
Santana TA, Trufelli DC, de Matos LL, Cruz FM, Del Giglio A. Meta-analysis of adjunctive non-NK1 receptor antagonist medications for the control of acute and delayed chemotherapy-induced nausea and vomiting. Support Care Cancer 2015; 23: 213-22.
Benze G, Geyer A, Alt-Epping B, Nauck F. Treatment of nausea and vomiting with 5HT3 receptor antagonists, steroids, antihistamines, anticholinergics, somatostatinantagonists, benzodiazepines and cannabinoids in palliative care patients: a systematic review. Schmerz (Berlin, Germany) 2012; 26: 481-99.
Whiting PF, Wolff RF, Deshpande S, Di Nisio M, Duffy S, Hernandez AV et al. Cannabinoids for medical use: a systematic review and meta-analysis. JAMA 2015; 313: 2456-73.
Australian New Zealand Clinical Trials Registry (ANZCTR). Sydney: ANZCTR; 2018 [cited 2018 May 8]. Available from URL: http://www.anzctr.org.au/TrialSearch.aspx?searchTxt=cANNABIS&isBasic=True
Mersiades A, Tognela A, Haber P, Stockler M, Lintzeris N, Simes J et al. 1805TiP Pilot and definitive randomised double-blind placebo-controlled trials evaluating an oral cannabinoid-rich THC/CBD cannabis extract for secondary prevention of chemotherapy-induced nausea and vomiting (CINV). Ann Oncol 2018; 29: viii640.
Mücke M, Weier M, Carter C, Copeland J, Degenhardt L, Cuhls H et al. Systematic review and meta-analysis of cannabinoids in palliative medicine. J Cachexia Sarcopenia Muscle 2018; 9: 220-34.
Luckett T, Phillips J, Lintzeris N, Allsop D, Lee J, Solowij N et al. Clinical trials of medicinal cannabis for appetite-related symptoms from advanced cancer: a survey of preferences, attitudes and beliefs among patients willing to consider participation. Intern Med J 2016; 46: 1269-75.
Therapeutic Goods Administration (TGA). Guidance for the Use of Medicinal Cannabis for the Prevention or Management of Nausea and Vomiting in Australia. Canberra: Department of Health, Commonwealth of Australia; 2017.
Therapeutic Goods Administration (TGA). Guidance for the Use of Medicinal Cannabis in the Treatment of Palliative Care Patients in Australia. Canberra: Department of Health, Commonwealth of Australia; 2017.
Therapeutic Goods Administration (TGA). Guidance for the Use of Medicinal Cannabis in Australia: Overview. Canberra: Department of Health, Commonwealth of Australia; 2017.
Therapeutic Goods Administration (TGA). Guidance for the Use of Medicinal Cannabis in Australia: Patient Information. Canberra: Department of Health, Commonwealth of Australia; 2017.
Lee J. Senate passes medicinal cannabis legislation. Sydney Morning Herald 2016 Dec 23.
Therapeutic Goods Administration (TGA). Access to Medicinal Cannabis Products. Canberra: Department of Health, Commonwealth of Australia; 2018.
Donovan KA, Chang YD, Oberoi-Jassal R, Rajasekhara S, Smith J, Haas M et al. Relationship of cannabis use to patient-reported symptoms in cancer patients seeking supportive/palliative care. J Palliat Med 2019; 22: 1191-5.
Morgan T. Tasmania's medicinal cannabis access scheme stalls as doctors remain hesitant, sceptical. Australian Broadcasting Corporation (ABC) News 2017.
Willis O. Medical marijuana is on the rise in Australia, but we still don't know a lot about how it works. Australian Broadcasting Corporation (ABC) News 2019.
Karanges E, Suraev A, Elias N, Manocha R, McGregor I. Knowledge and attitudes of Australian general practitioners towards medicinal cannabis: a cross-sectional survey. BMJ Open 2018; 8: e022101.